Study #2024-0180
Phase 1b/2 study of decitabine and venetoclax in combination with the targeted mutant IDH1 inhibitor olutasidenib
MD Anderson Study Status
Enrolling
Treatment Agent
Olutasidenib, Venetoclax, Decitabine, Decitabine/cedazuridine
Description
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mutant IDH1 Inhibitor Olutasidenib
Study phase:
Physician name:
Courtney DiNardo
Department:
Leukemia
For general questions about clinical trials:
1-844-513-2253
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.